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Systematic reviews of point-of-care tests for the 
diagnosis of urogenital Chlamydia trachomatis 
infections
Helen Kelly,1 Cordelia E M Coltart,1 Nitika Pant Pai,2 Jeffrey D Klausner,3 
Magnus Unemo,4 Igor Toskin,5 Rosanna W Peeling1
AbstrAct
background WHO estimates that 131 million new 
cases of urogenital Chlamydia trachomatis (CT) 
infections occur globally every year. Most infections are 
asymptomatic. Untreated infection in women can lead to 
severe complications. Screening and treatment of at-risk 
populations is a priority for prevention and control.
Objectives To summarise systematic reviews of the 
performance characteristics of commercially available 
point-of-care tests (POCT) for screening and diagnosis of 
urogenital CT infection.
Methods Two separate systematic reviews covering the 
periods 2004–2013 and 2010–2015 were conducted 
on rapid CT POCTs. Studies were included if tests were 
evaluated against a valid reference standard.
results In the first review, 635 articles were identified, 
of which 11 were included. Nine studies evaluated the 
performance of eight antigen detection rapid POCTs 
on 10 280 patients and two studies evaluated a near-
patient nucleic acid amplification test (NAAT) on 3518 
patients. Pooled sensitivity of antigen detection tests 
was 53%, 37% and 63% for cervical swabs, vaginal 
swabs and male urine, and specificity was 99%, 97% 
and 98%, respectively. The pooled sensitivity and 
specificity of the near-patient NAAT for all specimen 
types were >98% and 99.4%, respectively. The second 
review identified two additional studies on four antigen 
detection POCTs with sensitivities and specificities 
of 22.7%–37.7% and 99.4%–100%, respectively. A 
new two-step 15 min rapid POCT using fluorescent 
nanoparticles showed performance comparable to that 
of near-patient NAATs.
conclusions The systematic reviews showed that 
antigen detection POCTs for CT, although easy to use, 
lacked sufficient sensitivity to be recommended as a 
screening test. A near-patient NAAT shows acceptable 
performance as a screening or diagnostic test but 
requires electricity, takes 90 min and is costly. More 
affordable POCTs are in development.
IntrOductIOn
According to WHO estimates in 2012, urogenital 
chlamydial infection (etiological agent: Chlamydia 
trachomatis, CT) is the most common bacterial STI 
and approximately 131 million new cases occur 
globally every year.1 The highest number of esti-
mated cases was in the WHO Western Pacific Region 
(61 million), followed by the WHO American 
Region (25 million), WHO South-East Asian Region 
(14 million), WHO African Region (12 million), 
WHO Eastern Mediterranean Region (10 million) 
and WHO European Region (9 million).1 Most 
CT infections are asymptomatic. Undetected, CT 
infection may result in severe complications such 
as pelvic inflammatory disease, ectopic pregnancy, 
infertility, and enhanced transmission and acqui-
sition of HIV. Screening and treatment of at-risk 
populations is therefore a priority for prevention 
and control.
Highly accurate nucleic acid amplification tests 
(NAATs) are available in the developed world 
but since they require robust laboratory infra-
structure and trained personnel, these NAATs are 
neither affordable nor accessible to patients in 
the developing world, where access to laborato-
ries is limited and the STI burden remains high 
despite syndromic management. In the absence of 
screening programmes for asymptomatic infections 
and improved access to accurate laboratory diag-
nosis, the number of detected and reported cases is 
substantially lower than the number of real cases.1
NAATs are costly, technically demanding and 
laboratory based, requiring patients to come to the 
clinic to be screened and return for the result, or 
to mail in self-collected samples (vaginal swabs for 
women and urine specimens for men) and waiting 
for results to be sent by phone or internet.2 Point-
of-care tests (POCTs) that are affordable, sensitive, 
specific, user-friendly, rapid and robust, equip-
ment-free and delivered to end-users (ASSURED) 
would have considerable implications for STI 
control in less resourced settings and in well-re-
sourced settings. Using accurate and rapid CT 
POCTs, patients can be promptly diagnosed and 
appropriately treated at presentation, preventing 
complications, and ongoing transmission, and 
offering opportunities for counselling and contact 
notification. Simple rapid POCTs for the diagnosis 
and screening of CT infections are commercially 
available, but there are limited data on their perfor-
mance.4 5 The WHO STI point-of-care (POC) diag-
nostic initiative, coordinated by the Department 
of Reproductive Health and Research at WHO, 
including the UNDP/UNFPA/Unicef/WHO/World 
Bank Special Programme of Research, Development 
and Research Training in Human Reproduction, 
aims to facilitate and support access to quality-as-
sured STI POCTs within national STI programmes 
through providing advice to WHO Member States 
and other relevant public health institutions on the 
performance and operational characteristics of new 
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commercially available STI diagnostic tests that can be used at 
the POC across all countries.
This paper describes the findings from two systematic reviews 
of the performance and operational characteristics of commer-
cially available POCTs for the diagnosis of urogenital and extra-
genital CT infection.
MethOds
the first systematic review
The first systematic review was conducted in 2013–2014 by 
authors from the London School of Hygiene and Tropical Medi-
cine, UK, in collaboration with McGill University, Canada, 
in accordance with PRISMA (Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses) guidelines, which aim 
to advance the reporting of systematic reviews and meta-anal-
yses by improving the transparency and completeness of infor-
mation.6 Only rapid and simple POCTs that met the ASSURED 
criteria3 were included.
Search terms and strategy
MEDLINE and GLOBAL HEALTH databases were searched 
from 1 January 2004 to 31 December 2013. Search terms were 
as follows: (chlamydia AND Chlamydia trachomatis AND C. 
trachomatis) AND (point-of-care OR POC test OR POCT OR 
rapid test* OR rapid assay* OR diagnos* OR near patient OR 
screening OR urine dipstick) AND (evaluation OR performance 
characteristics OR validation OR performance OR sensitivity 
OR specificity).
Systematic reviews were identified first. If no systematic 
reviews were published on the topic, case–control, cross-sec-
tional or cohort studies were identified.
Inclusion criteria
Eligibility criteria were defined using PICOS (Population, Inter-
ventions, Comparisons, Outcomes, Study Design) criteria as 
shown in table 1. Studies evaluating the accuracy and/or preci-
sion of any CT POCT commercially available at the time of the 
review were considered for inclusion.
Exclusion criteria
Studies were excluded if the test was not a rapid test for CT, if 
diagnostic accuracies were not compared with an appropriate 
reference standard, and if the studies did not report data to 
allow for calculation of diagnostic accuracy. Studies reporting 
POCT analytical performance and POCTs in development were 
excluded.
Data extraction
Two reviewers independently extracted data from the included 
studies meeting the inclusion criteria. Items for data extraction 
for each POCT included: study (journal, author, year); location 
(country, healthcare level where study was performed); field/
laboratory location where tested (peripheral/reference); test 
method; reference/gold standard; specimen type; sample size; 
population; age range; genital symptoms; sensitivity; specificity; 
positive predictive value; negative predictive value; receiver 
operating characteristics: number of steps; major equipment 
required for test; time to result; and CT prevalence. Disagree-
ments were resolved by consensus or external advisors.
Data synthesis and statistical analysis
Descriptive analyses were performed using STATA V.14 (STATA, 
College Station, TX, USA). For each study, the sensitivity and 
specificity along with 95% CIs, compared with the reference 
standard, were calculated. Forest plots were generated to display 
sensitivity and specificity estimates.
Meta-analysis
The heterogeneity in the forest plots was assessed by visually 
examining the CIs of individual studies, and in summary Hier-
archical Summary Receiver Operating Characteristic (HSROC) 
plots (by examining the width of the prediction region, with a 
wider prediction region suggesting more heterogeneity). Hetero-
geneity in terms of the sample types by index test for CT and 
also prespecified subgroups such as different specimen types 
were examined. A bivariate random-effects model was used and 
meta-analyses were carried out in STATA. For this review of 
CT POCTs, a meta-analysis for a predefined sample type was 
only carried out if at least four studies were available.
Metaregression
Additional heterogeneity was anticipated with respect to 
samples, patient population groups and prevalence within the 
prespecified subgroups. Therefore, a bivariate metaregres-
sion model in STATA was selected for use under the assump-
tion that the pooled sensitivity and specificity were different in 
each subgroup, but not the between-study variance-covariance 
matrix. The metaregression assessment was performed only on 
studies with the same reference standard. It was also presumed 
that the effect of the covariate would not differ between the 
different reference standards.
Sensitivity analysis
Sensitivity analyses could not be performed due to lack of addi-
tional covariate data.
table 1 Inclusion criteria (PICOS criteria)
Population Any sexually active populations in any geographical location
Interventions (index tests) Any commercially available technology used for Chlamydia trachomatis POCTs in the field (excluding those tested in laboratory settings)
Comparators Studies using an acceptable reference standard that satisfy the STARD checklist (quality assessment)
Acceptable reference standard—culture and/or NAAT
Outcomes Evaluations of accuracy and/or precision. Include studies calculating sensitivity, specificity, PPV and NPV including 95% CI, ease of use and 
acceptability by user
Study design Evaluation of studies published in peer-reviewed literature. No grey literature was included
Other English language only, human subjects only, 1 January 2004 to 31 December 2013
Sample type: vaginal, cervical, urethral or urine samples
NAAT, nucleic acid amplification test; NPV, negative predictive value; PICOS, Population, Interventions, Comparisons, Outcomes, Study Design; POCT, point-of-care test; PPV, 
positive predictive value; STARD, Standards for the Reporting of Diagnostic Accuracy Studies.
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Formal assessment of publication bias using methods such as 
funnel plots or regression tests was not performed because such 
techniques are not considered to be valid for diagnostic accuracy 
reviews.
Data quality
Quality of the studies included was assessed according to the 
STARD Criteria and Checklist.7
the second systematic review
The second systematic review was conducted in 2015 by authors 
from the University of California, Los Angeles, USA, for papers 
published from January 2010 to August 2015.4
Search terms and strategy
The search was conducted according to PRISMA guidelines6 
in PubMed using search terms as follows: sexually transmitted 
diseases or sexually transmitted infection∗ and chlamydia* and 
(point-of-care and (rapid test or diagnostic or screening or test)).
Abstracts of all search results and the full text of all potentially 
eligible articles were reviewed. This search yielded 61 articles 
whose abstracts were evaluated to determine whether they fit 
the inclusion criteria.
Inclusion criteria
The inclusion criteria were (1) publications including Chlamydia 
as STIs; (2) publications that date from January 2010 through 
August 2015; (3) publications relating to diagnostics; (4) publi-
cations published in English; and (5) original research.
Exclusion criteria
The exclusion criteria were (1) publications not covering CT; 
(2) publications including those infections but not in the sexu-
ally transmissible form; (3) publications published before 2010; 
and (4) publications not evaluating POC diagnostics using a valid 
reference standard assay.
Articles were sorted into the following subject categories 
and stratified based on: (1) performance evaluations, (2) cost 
analyses, (3) acceptability and feasibility trials and (4) proof of 
concept studies.
results
The first systematic review identified a total of 635 papers, of 
which 557 were excluded based on their title and abstract. An 
additional 68 articles were excluded after a review of the full 
text, leaving 10 articles for data extraction. An additional article 
was identified by a study adviser (figure 1).
The second review by Herbst de Cortina et al identified 33 
articles, of which 8 were on the performance of tests to detect 
genital CT infection.4 Of the eight studies, two evaluated the 
performance of Gram-stained urethral smears and one evalu-
ated an automated urine flow cytometry compared with NAATs. 
Since microscopy and flow cytometry are not POCTs, they are 
not included in this review. Of the five studies included in this 
review, three were already identified in the first review and two 
studies published in 2015 and 2016 were added to the data 
extraction for this review.
Operational characteristics of POcts included in the review
The two systematic reviews described the evaluation of nine 
brands of antigen detection POCTs and one NAAT that can be 
labelled as near patient as it is an automated sample-in answer-out 
assay that requires 2 min of hands-on time and is designed for 
both laboratories and clinic settings (table 2). The antigen detec-
tion tests included six immunochromatographic tests in a lateral 
format, one test using optical detection, one using enzyme detec-
tion and one using fluorescent nanoparticles.
data extracted from the studies
The two systematic reviews identified 11 studies that evaluated 
the performance of 9 brands of CT antigen detection POCTs 
on 11 889 study participants from 10 countries. Two studies 
described evaluation of the performance of a near-POC NAAT 
on 3568 study participants from two countries. Reference stan-
dard assays used included PCR assays (Roche Molecular Systems, 
USA), ligase chain reaction assay (Abbott Diagnostics, USA), 
strand displacement amplification assay, ProbeTec ET assay 
(Becton Dickinson, USA) and transcription-mediated amplifica-
tion assay (Aptima, GenProbe, now Hologic, USA).
Table 3 displays data extracted from the studies evaluating 
the performance of CT antigen detection POCTs and near-POC 
NAAT in both systematic reviews.
Antigen detection rapid POCTs exhibited high specificity 
across all specimen types (range 97%–100%), the pooled sensi-
tivity was 37% for vaginal swabs (95% CI 22.9% to 52.9%; 
range 17.1%–74.2%), 53% for endocervical swabs (95% CI 
34.7% to 70.8%; range 22.7%–87%) and 63% for urine (95% 
CI 43.2% to 78.5%; range 49.7%–88.2%) (table 4). The aQcare 
Chlamydia TRF kit, which is a fluorescent nanoparticle-based 
lateral flow assay, was the best performing antigen detection 
POCT, with sensitivities and specificities comparable to that of 
near-patient NAATs.8
Although CT antigen detection rapid POCTs exhibited high 
specificity across all specimen types (range 97%–100%), the 
pooled sensitivity was 37% for vaginal swabs (95% CI 22.9% 
to 52.9%; range 17.1%–74.2%), 53% for endocervical swabs 
(95% CI 34.7% to 70.8%; range 22.7%–87%) and 63% for 
urine (95% CI 43.2% to 78.5%; range 49.7%–88.2%) (table 4). 
The aQcare Chlamydia TRF kit, which is a fluorescent nanopar-
ticle-based lateral flow assay, was the best performing antigen 
Figure 1 PRISMA (Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses) flow diagram for study selection in systematic 
review 1.
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detection POCT, with sensitivities and specificities comparable 
to that of near-patient NAATs.8 The best performing test overall 
was the Xpert CT/NG, a Food and Drug Administration-ap-
proved real-time PCR assay.
The sensitivity of the Cepheid GeneXpert assay showed no 
significant difference between self-collected vaginal swabs 
(98.7%), cervical swabs (97.4%), female urine (97.6%) and 
male urine specimens (97.5%) with specificities ranging from 
99.4% to 99.9%. The sensitivity and specificity of this assay for 
rectal swabs are 86.0% and 99.2% respectively. In particular, for 
POCTs we are interested in specimens that are easy to collect. 
The overall sensitivity and specificity of antigen detection 
POCTs for vaginal swabs from the two systematic reviews are 
graphically represented in figure 2A,B and those for urine spec-
imens in figure 3A,B.
According to the STARD criteria7 relevant to POCTs, the 
quality of the papers included was acceptable, with noted omis-
sions in the categories describing whether operators were trained 
to perform the tests, mechanism for blinding between the results 
of the index and reference tests and documentation of the 
frequency of indeterminate results (table 5).
dIscussIOn
The two systematic reviews described in this paper showed 
that while the specificity of most CT antigen detection POCTs 
was >97%, their sensitivities were suboptimal, especially when 
used with vaginal swabs. Nevertheless, they are being used, espe-
cially in countries lacking the capacity for stringent regulatory 
review and approval. Women who had false negative test results 
due to low sensitivity would not be treated and could subse-
quently develop long-term reproductive sequelae such as pelvic 
inflammatory disease, ectopic pregnancy and tubal infertility. 
Using a model, Gift et al9 showed that a POCT with a sensi-
tivity of 65% can lead to more patients being treated for genital 
chlamydial infections than a more accurate NAAT because only 
50% of patients who were screened for chlamydia returned for 
their test results within 3 weeks. Moreover, by the time they 
returned, 3% of women had developed pelvic inflammatory 
disease. Hence, POCTs offer an important opportunity to treat 
any infected patient and initiate partner notification in the same 
clinic visit.
Although the sensitivity of POCTs is higher for cervical swabs 
than vaginal swabs, POCTs are best used with specimens that are 
easy to collect such as urine for men or vaginal swabs, which are 
self-collected or collected by a healthcare provider. Hurly et al10 
compared the performance of the Chlamydia Rapid Test (Diag-
nostics for the Real World, Cambridge, UK) and ACON CT test 
for men and women, and found lower sensitivities for urine from 
men (41.4%–43.8%) compared that for vaginal swabs (66.7%–
74.2%) for both POCTs. The authors attributed this difference to 
the CT load in these specimen types. Wisniewski et al11 showed 
that for urine samples, there is significantly more chlamydia in 
the first 4–5 mL of the void than subsequent aliquots.
A single study on a POCT based on fluorescent nanoparti-
cles requiring only 15 min turnaround time showed promising 
performance characteristics that are comparable to near-patient 
NAATs. More evaluations of this POCT would be necessary to 
determine if these performance characteristics are reproducible.
Gaydos et al12 evaluated both symptomatic and asymptomatic 
women at reproductive health clinics, and showed excellent 
accuracy for the Cepheid Xpert CT/NG test. In contrast to the 
antigen detection POCTs, the Xpert CT/NG did not show any 
significant difference in performance between specimen types. 
Goldenberg et al13 showed that the Xpert test has adequate 
table 2  Chlamydia trachomatis POCTs identified in the two systematic reviews
test Manufacturer type of test
time to 
result
room temperature 
storage studies
Point-of-care antigen detection tests
ACON
Chlamydia and NG/CT Duo
ACON, China  ICT <30 min Yes Hurly et al10
Nuñez-Forero et al20
aQcare Chlamydia TRF kit* Medisensor, Korea Lateral flow assay using 
fluorescent nanoparticles
15 min Yes Ham et al21
BioRapid BioKit, Spain ICT 20 min Yes van Dommelen et al22
BioStar 
Chlamydia†
Inverness Medical, USA Optical immunoassay 30 min Yes Bandea et al23
Chlamydia Rapid Test  DRW, UK ICT 25 min Yes Saison et al24
Wisniewski et al11
Nadala et al25
van der Helm et al26
Hurly et al10
Clearview Alere, USA ICT 30 min Reagents storage at 
2°C–8°C
Yin et al8
Saison et al24
Chlamydia Test Card Ultimed, Germany ICT 10 min Yes Sabidó et al27
HandiLab-C HandiLab, USA Enzyme detection <15 min Yes Michel et al28
van Dommelen et al22
QuickVue Quidel, USA ICT 15 min Yes van Dommelen et al22
Near point-of-care NAAT
Xpert CT/NG Cepheid, USA Real-time PCR 87 min Yes Goldenberg et al13
Gaydos et al12
*aQcare Chlamydia TRF test is a quantitative assay which uses europium-chelated nanoparticles in a lateral flow format. The signal is measured using a portable, small 
fluorescence reader (dimensions 348×240×221 mm).
†The BioStar assay is an optical immunoassay which is a proprietary technology that allows direct visual detection of the binding reactions between antigens and antibodies on 
a thin film.
DRW, Diagnostics for the Real World; ICT, immunochromatographic test; NAAT, nucleic acid amplification test; POCT, point-of-care test.
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performance with rectal swabs. Although more accurate, 
near-patient NAATs are more expensive than antigen detection 
POCTs. However, the Cepheid platform has two features which 
are advantages. First, it allows random access in that detection 
of different pathogens on its test menu can be initiated any 
time as each cell is an independent nucleic acid amplification 
and detection reaction. Second, the Cepheid platform, like most 
other near-patient molecular platforms, is polyvalent in that the 
equipment can be used with cartridges for over 20 pathogens. 
This makes the testing more cost-effective.
In selecting a test for screening of asymptomatic popula-
tions or diagnosis of symptomatic patients, health providers 
and control programmes need to consider the trade-off 
between accuracy and affordability for their epidemiological 
setting and what patients are willing to pay and whether they 
are willing to wait for 90 min versus 15–30 min. Gift et al 
table 4 Pooled performance of the POC antigen detection and near-patient NAATs for different specimen types
specimen type
Antigen detection point-of-care tests near-patient nAAts
number of 
studies; n sensitivity (95% cI) specificity (95% cI) number of studies; n sensitivity % (95% cI) specificity % (95% cI)
Cervical swab 8; 4588 53.1% (34.7 to 70.8) 98.9% (98.0 to 99.4) 1; 1713 97.4% 99.6%
Vaginal swab 10; 6252 36.6% (22.9 to 52.9) 96.9% (94.0 to 98.4) 1; 1710 98.7% 99.4%
Male urine 5; 2568 62.5% (43.2 to 78.5) 98.0% (95.1 to 99.0) 1; 1386 97.5% 99.9%
Female urine – – – 1; 1718 97.6% 99.8%
Male rectal swab – – – 1; 409 86% 99.2%
NAAT, nucleic acid amplified test; POC, point of care.
Figure 2 (A) Meta-analysis of Chlamydia trachomatis antigen detection POC test performance using vaginal swabs in 10 studies. (B)HSROC for 
C. trachomatis antigen detection POC test performance using vaginal swabs in 10 studies. AUC, area under the curve; POC, point of care; SENS, 
sensitivity; SPEC, specificity.
Figure 3 (A) Meta-analysis of Chlamydia trachomatis antigen detection POC test performance using urine samples in five studies among 
men. (B) HSROC for C. trachomatis antigen detection POC test using urine samples in 5five studies among men. AUC, area under the curve; POC, point 
of care; SENS, sensitivity; SPEC, specificity.
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described the rapid test paradox in a model of chlamydial 
screening in which a rapid test of 65% sensitivity led to more 
infected patients being treated than using a NAAT with higher 
accuracy because of low patient return rates for results.9 Adams 
et al14 examined the need to modify patient pathways to take 
full advantage of near-patient NAATs, which can reduce cost 
and clinician time and may lead to more efficient and appro-
priate care for patients compared with standard of care which 
is off-site laboratory testing and having to return for test results 
and treatment. In a simulation of 1.2 million patients seeking 
STI care across the UK, it was estimated that POC testing can 
be cost-saving and reduce overtreatment of patients who are 
diagnosed using a syndromic approach.15 POC testing in this 
scenario can prevent 189 cases of pelvic inflammatory disease 
and 17 561 cases of onward transmission.
The quality of the studies included in these systematic 
reviews is generally satisfactory (table 5). The main short-
comings include omission in describing training in spec-
imen storage and processing, how indeterminate results are 
managed, and blinding between index and reference test 
results.
Our review had several limitations. First, the first systematic 
review only used MEDLINE and GLOBAL HEALTH data-
bases and the second systematic review only used PubMed to 
find relevant articles. Second, there are existing commercial 
POCTs which have been approved for use but were not eval-
uated in any publications between January 2000 and August 
2015, preventing their inclusion in this paper. A number of 
studies that are proof of concept studies or analytical perfor-
mance studies from promising new technology platforms have 
not been included. They were described in the second system-
atic review.4
Emerging new technologies, including isothermal ampli-
fication technologies, promise major advancements in the 
field of rapid POCTs for STIs in the near future.16 A number 
of novel POC molecular platforms have been developed for 
HIV early infant diagnosis and viral load and are now being 
adapted for the diagnosis of STIs.17 18 As more of these molec-
ular POCTs become available, the cost to produce, distribute 
and use these tests will also decrease, thus increasing accessi-
bility and affordability in less resourced settings, where STI 
prevalence is highest and the burden of adverse outcomes is 
greatest.19
cOnclusIOns
The systematic reviews showed that antigen detection POCTs 
for CT, although easy to use, lacked sufficient sensitivity to be 
recommended as screening tests. Currently available near-POC 
NAATs have acceptable performance characteristics to be used 
as screening and diagnostic tests but need a source of electricity, 
have a relatively long turnaround time of approximately 90 min 
and are too costly for widespread use, especially in low resource 
settings. Other novel POC molecular assays are under develop-
ment and may soon be available to improve chlamydial screening 
and diagnosis in less resourced settings as well as more well-re-
sourced settings. However, before the introduction of these 
novel POCTs it is crucial to evaluate their performance and 
operational characteristics and their acceptability to patients and 
healthcare facilities. This is a high priority for the WHO STI 
POC diagnostic initiative in the coming years as countries strive 
to reduce the burden of STIs.
Acknowledgements We are grateful to Rachel Chater for assistance with the 
preparation of the manuscript.t
ab
le
 5
 
As
se
ss
m
en
t o
f t
he
 q
ua
lit
y 
of
 th
e 
st
ud
ie
s 
in
cl
ud
ed
 in
 th
e 
fir
st
 s
ys
te
m
at
ic
 re
vi
ew
st
A
rd
 c
ri
te
ri
a7
10
%
20
%
30
%
40
%
50
%
60
%
70
%
80
%
90
%
10
0%
1.
 E
as
ily
 id
en
tifi
ab
le
 a
s 
a 
st
ud
y 
of
 d
ia
gn
os
tic
 a
cc
ur
ac
y
2.
 S
ta
te
 th
e 
re
se
ar
ch
 q
ue
st
io
ns
 o
r s
tu
dy
 a
im
s
3.
 D
es
cr
ib
es
 th
e 
st
ud
y 
po
pu
la
tio
n:
 th
e 
in
cl
us
io
n 
an
d 
ex
cl
us
io
n 
cr
ite
ria
, t
he
 s
et
tin
g 
an
d 
th
e 
lo
ca
tio
ns
 w
he
re
 th
e 
da
ta
 w
er
e 
co
lle
ct
ed
4.
 D
es
cr
ib
es
 p
ar
tic
ip
an
t r
ec
ru
itm
en
t a
nd
 s
am
pl
in
g 
(p
ro
sp
ec
tiv
e 
or
 re
tr
os
pe
ct
iv
e 
st
ud
y)
5.
 D
es
cr
ib
es
 th
e 
te
st
 u
nd
er
 e
va
lu
at
io
n
6.
 D
es
cr
ib
es
 th
e 
re
fe
re
nc
e 
st
an
da
rd
 a
nd
 it
s 
ra
tio
na
le
7.
 D
es
cr
ib
es
 s
pe
ci
m
en
 a
cq
ui
si
tio
n
8.
 D
es
cr
ib
es
 s
pe
ci
m
en
 s
to
ra
ge
9.
 D
es
cr
ib
es
 tr
ai
ni
ng
 in
 s
pe
ci
m
en
 p
ro
ce
ss
in
g
10
. D
es
cr
ib
es
 b
lin
di
ng
 m
ec
ha
ni
sm
 b
et
w
ee
n 
in
de
x 
an
d 
re
fe
re
nc
e 
te
st
 re
su
lts
11
. U
se
s 
ap
pr
op
ria
te
 s
ta
tis
tic
al
 a
na
ly
si
s
12
. S
ho
w
s 
cr
os
s-
ta
bu
la
tio
n 
of
 re
su
lts
 o
f i
nd
ex
 a
nd
 re
fe
re
nc
e 
te
st
s
13
. E
st
im
at
es
 d
ia
gn
os
tic
 a
cc
ur
ac
y 
w
ith
 s
ta
tis
tic
al
 u
nc
er
ta
in
ty
 (C
Is
)
14
. S
ho
w
s 
ho
w
 in
de
te
rm
in
at
e 
re
su
lts
 a
re
 h
an
dl
ed
15
. D
es
cr
ib
es
 v
ar
ia
bi
lit
y 
an
d 
su
bg
ro
up
 a
na
ly
si
s
16
. D
is
cu
ss
es
 c
lin
ic
al
 a
pp
lic
ab
ili
ty
 o
f fi
nd
in
gs
group.bmj.com on January 4, 2018 - Published by http://sti.bmj.com/Downloaded from 
S30 Kelly H, et al. Sex Transm Infect 2017;93:S22–S30. doi:10.1136/sextrans-2016-053067
review
contributors RWP and IT designed the review. HK and CEMC conducted the 
searches and data extraction. NPP performed the analyses. All authors contributed to 
the finalisation of the manuscript.
Funding This work was funded by the UNDP-UNFPA-Unicef-WHO-World Bank 
Special Programme of Research, Development and Research Training in Human 
Reproduction (HRP), a cosponsored programme executed by WHO (Contract No 
SPHQ13-APW-4095).
disclaimer  The author(s) is(are) staff member(s) of the World Health Organization. 
The author(s) alone is(are) responsible for the views expressed inthis publication and 
they do not necessarily represent the views,decisions or policies of the World Health 
Organization.
competing interests None declared.
Provenance and peer review Commissioned; externally peer reviewed.
Open Access © World Health Organization [2017]. Licensee BMJ Publishing Group 
Limited. This is an open access article distributed under the terms of the Creative 
Commons Attribution IGO License (http:// creativecommons. org/ licenses/ by/ 4. 0/ igo), 
which permits use, distribution, and reproduction for non-commercial purposes in 
any medium, provided the original work is properly cited. In any reproduction of 
this article there should not be any suggestion that WHO or this article endorse any 
specific organization or products. The use of the WHO logo is not permitted. This 
notice should be preserved along with the article’s original URL.
RefeRences
 1 Newman L, Rowley J, Vander Hoorn S, et al. Global estimates of the prevalence and 
incidence of four curable sexually transmitted infections in 2012 based on systematic 
review and global Reporting. PLoS One 2015;10:e0143304.
 2 Unemo M, Ballard R, Ison C, et al. Laboratory diagnosis of sexually transmitted 
infections, including HIV. Geneva, Switzerland: WHO, 2013.
 3 Peeling RW, Holmes KK, Mabey D, et al. Rapid tests for sexually transmitted infections 
(STIs): the way forward. Sex Transm Infect 2006;82(suppl 5):v1–6.
 4 Herbst de Cortina S, Bristow CC, Joseph Davey D, et al. A systematic review of point 
of care testing for chlamydia trachomatis, neisseria gonorrhoeae, and trichomonas 
vaginalis. Infect Dis Obstet Gynecol 2016;2016:ID 4386127.
 5 Gaydos C, Hardick J. Point of care diagnostics for sexually transmitted infections: 
perspectives and advances. Expert Rev Anti Infect Ther 2014;12:657–72.
 6 Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews 
and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.
 7 Cohen JF, Korevaar DA, Altman DG, et al. STARD 2015 guidelines for reporting 
diagnostic accuracy studies: explanation and elaboration. BMJ Open 2016;6:e012799. 
http:// bmjopen. bmj. com/ content/ 6/ 11/ e012799. abstract
 8 Yin YP, Peeling RW, Chen XS, et al. Clinic-based evaluation of Clearview chlamydia 
MF for detection of Chlamydia trachomatis in vaginal and cervical specimens from 
women at high risk in China. Sex Transm Infect 2006;82(suppl V):v33–7.
 9 Gift TL, Pate MS, Hook EW, et al. The rapid test paradox: when fewer cases detected 
lead to more cases treated: a decision analysis of tests for Chlamydia trachomatis. Sex 
Transm Dis 1999;26:232–40.
 10 Hurly DS, Buhrer-Skinner M, Badman SG, et al. Field evaluation of the CRT and ACON 
Chlamydia point-of-care tests in a tropical, low-resource setting. Sex Transm Infect 
2014;90:179–84.
 11 Wisniewski CA, White JA, Michel CE, et al. Optimal method of collection of first-void 
urine for diagnosis of Chlamydia trachomatis infection in men. J Clin Microbiol 
2008;46:1466–9.
 12 Gaydos CA, Van Der Pol B, Jett-Goheen M, et al. Performance of the Cepheid CT/
NG Xpert rapid PCR test for detection of Chlamydia trachomatis and Neisseria 
gonorrhoeae. J Clin Microbiol 2013;51:1666–72.
 13 Goldenberg SD, Finn J, Sedudzi E, et al. Performance of the GeneXpert CT/NG 
assay compared to that of the Aptima AC2 assay for detection of rectal Chlamydia 
trachomatis and Neisseria gonorrhoeae by use of residual aptima samples. J Clin 
Microbiol 2012;50:3867–9.
 14 Adams EJ, Ehrlich A, Turner KM, et al. Mapping patient pathways and estimating 
resource use for point of care versus standard testing and treatment of 
Chlamydia and gonorrhoea in genitourinary medicine clinics in the UK. BMJ Open 
2014;4:e005322.
 15 Turner KM, Round J, Horner P, et al. An early evaluation of clinical and economic costs 
and benefits of implementing point of care NAAT tests for Chlamydia trachomatis and 
Neisseria gonorrhoea in genitourinary medicine clinics in England. Sex Transm Infect 
2014;90:104–11.
 16 WHO STI POC Diagnostics landscape. http:// who. int/ reproductivehealth/ topics/ rtis/ 
Diagnostic_ Landscape_ 2016. pdf? ua=1 (accessed Mar 2 2017).
 17 HIV/AIDS diagnostics technology landscape – semi-annual update. UNITAID www. 
unitaid. eu/ images/ UNITAID_ 2013_ Semi- annual_ Update_ HIV_ Diagnostics_ 
Technology_ Landscape. pdf
 18 Peeling RW, McNerney R. Emerging technologies in point-of-care molecular 
diagnostics for resource-limited settings. Expert Rev Mol Diagn 2014;14:525–34.
 19 Adachi K, Nielsen-Saines K, Klausner JD. Chlamydia trachomatis infection in 
Pregnancy: the global challenge of preventing adverse pregnancy and infant 
outcomes in Sub-Saharan Africa and Asia. Biomed Res Int 2016;2016:1–21.
 20 Nuñez-Forero L, Moyano-Ariza L, Gaitán-Duarte H, et al. Diagnostic accuracy of rapid 
tests for sexually transmitted infections in symptomatic women. Sex Transm Infect 
2016;92:24–8.
 21 Ham JY, Jung J, Hwang BG, et al. Highly sensitive and novel point-of-care system, 
aQcare Chlamydia TRF kit for detecting Chlamydia trachomatis by using europium 
(Eu) (III) chelated nanoparticles. Ann Lab Med 2015;35:50–6.
 22 van Dommelen L, van Tiel FH, Ouburg S, et al. Alarmingly poor performance in 
Chlamydia trachomatis point-of-care testing. Sex Transm Infect 2010;86:355–9.
 23 Bandea CI, Koumans EH, Sawyer MK, et al. Evaluation of the Rapid BioStar Optical 
immunoassay for detection of Chlamydia trachomatis in Adolescent women. J Clin 
Microbiol 2009;47:215–6.
 24 Saison F, Mahilum-Tapay L, Michel CE, et al. Prevalence of Chlamydia trachomatis 
infection among low- and high-risk Filipino women and performance of Chlamydia 
rapid tests in resource-limited settings. J Clin Microbiol 2007;45:4011–7.
 25 Nadala EC, Goh BT, Magbanua JP, et al. Performance evaluation of a new rapid urine 
test for chlamydia in men: prospective cohort study. BMJ 2009;339:b2655.
 26 van der Helm JJ, Sabajo LO, Grunberg AW, et al. Point-of-care test for detection of 
urogenital chlamydia in women shows low sensitivity. A performance evaluation study 
in two clinics in Suriname. PLoS One 2012;7:e32122.
 27 Sabidó M, Hernández G, González V, et al. Clinic-based evaluation of a rapid point-
of-care test for detection of Chlamydia trachomatis in specimens from sex workers in 
Escuintla, Guatemala. J Clin Microbiol 2009;47:475–6.
 28 Michel CE, Saison FG, Joshi H, et al. Pitfalls of internet-accessible diagnostic tests: 
inadequate performance of a CE-marked Chlamydia test for home use. Sex Transm 
Infect 2009;85:187–9.
Key messages
 ► Diagnostic tests are needed for detecting genital chlamydial 
infections but there are limited data on their performance 
and operational characteristics for use in the developing 
world. Systematic reviews show that antigen detection 
tests that can be used at the point of care (POC) have good 
specificity but suboptimal sensitivity.
 ► Near-patient molecular assays are highly accurate but require 
electricity, 90 min turnaround time and are too costly for use 
in low resource settings.
 ► Promising novel POC technologies that are accurate have 
shorter turnaround time and are less costly in development.
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